FDA Orange Book · active-ingredient family
Sarecycline hydrochloride
Sarecycline hydrochloride is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:SEYSARA · NDA 209521
1
Brand (NDA)
0
Generics (ANDA)
4
Listed patents
0
Exclusivity periods
Brand (NDA) products · tablet
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| SEYSARARLD×3 | ALMIRALL | NDA 209521 | — | Oct 01, 2018 |
Listed patents (4)
| Patent | Expires | In | Type |
|---|---|---|---|
| 9481639 | Aug 10, 2028 | in 2 yr 2 mo | U-2409 |
| 8513223 | Dec 07, 2029 | in 3 yr 6 mo | U-2406 |
| 8318706 | Jan 03, 2032 | in 5 yr 7 mo | SubstanceProductU-2405 |
| 9255068 | Feb 09, 2033 | in 6 yr 9 mo | SubstanceProductU-2407 |
Sarecycline hydrochloride — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

